Rationale and Design of a Study to Assess the Engagement and Usefulness of the Care4Today Connect Digital Health Application for Disease Management in Coronary Artery Disease and Peripheral Artery Disease (iPACE‐CVD Study)
Authors
Luis Ortega‐Paz (ORCID: https://orcid.org/0000-0002-9567-3253)
Rationale and Design of a Study to Assess the Engagement and Usefulness of the Care4Today Connect Digital Health Application for Disease Management in Coronary Artery Disease and Peripheral Artery Disease (iPACE‐CVD Study)
Luis Ortega‐Paz, Dhanunjaya Lakkireddy, Kristofer M. Charlton-Ouw, Dominick J. Angiolillo et al.
Citations
2 citations
Journal
Clinical Cardiology
Topics
Medication Adherence and Compliance
Field-Weighted Citation Impact (FWCI)
1.01
article
Rationale and Design of a Study to Assess the Engagement and Usefulness of the Care4Today Connect Digital Health Application for Disease Management in Coronary Artery Disease and Peripheral Artery Disease (iPACE‐CVD Study)
Luis Ortega‐Paz, Dhanunjaya Lakkireddy, Kristofer M. Charlton-Ouw, Dominick J. Angiolillo, Stephanie Juan, B. Woods, Ante Harxhi, Mohannad Bisharat, Eva Michaud, Gregory P. Fontana, Simrati Kaul, Marc P. Bonaca, Syed M. Peeran, C.V. Damaraju, Brian Jefferson
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Clinical CardiologyVol. 47(12)
Institutions
Johnson & Johnson (United States) (US), West Health (US), Jackson Memorial Hospital (US), University of Florida (US), Centennial Medical Center (US), Memorial Hospital (US), Portsmouth Regional Hospital (US), Los Robles Hospital & Medical Center (US), Janssen (United States) (US), Janssen Scientific Affairs (United States), University of Houston (US), University of Colorado Anschutz Medical Campus (US), University of Colorado Denver (US), Florida College (US)
Funders
Abbott Laboratories, Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Yale University, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Medpace, Osiris Therapeutics, Array BioPharma, University of Pittsburgh, CSL Behring, Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Prothena, Audentes Therapeutics, Kowa Company, Agios Pharmaceuticals, Janssen Scientific Affairs, Saint Luke's Health System, JenaValve, ARCA Biopharma, Insmed, Novo Nordisk, Silence Therapeutics, Esperion Therapeutics, Feinstein Institutes for Medical Research